Therapy of lymphoid and undifferentiated XXXX in @entity9638 with continuous @entity1891 and @entity632 infusions plus high-dose decadron.

@entity1 @entity632 @entity8487 @entity37438 @entity66 @entity706 @entity137 @entity221 @entity9638 @entity786 @entity281 @entity1891 @entity4609 @entity1860 @entity2145
Thirty @entity1 with @entity8487 chromosome-positive lymphoid (20 @entity1 ) or undifferentiated (ten @entity1 ) @entity1860 in @entity9638 were treated with 0.4 mg of @entity1891 by continuous intravenous infusion ( @entity4609 ) daily for 4 days; ( @entity632 ) 12 mg/m2 of @entity632 (Adria Laboratories, Columbus, @entity2145 ) by continuous intravenous infusion daily for 4 days; and 40 mg of @entity37438 daily on days 1 through 4, 9 through 12, and 17 through 20 (VAD). Course 2 was given starting on day 24 with the addition of @entity786 1 g/22. Overall nine @entity1 achieved complete remission (30%) and three attained a partial remission (10%), for an overall response rate of 40%. Four @entity1 expired during induction whereas 14 had resistant disease. Response rate was significantly higher for @entity1 with lymphoid compared to undifferentiated morphology (55% versus 10%; P = 0.05). In @entity706 , @entity66 was associated with a higher response rate compared to Calla-negative disease (75% versus 25%; P = 0.08). Eleven @entity1 developed @entity281 , and seven had @entity221 without documented @entity281 . The median overall survival was 29 weeks. Median survival was 43 weeks for @entity1 achieving complete remission and 20 weeks for those with resistant disease. Remission duration was 39 weeks. After primary and salvage therapy, nine @entity1 are alive, six of them in continuous remission for 19+ to 112+ weeks. The authors conclude that VAD chemotherapy is an effective regimen with acceptable @entity137 in @entity1 with @entity706 especially those with @entity66 . Alternate induction regimens for undifferentiated disease and for maintenance therapy are currently being investigated.
